OncoMatch/Clinical Trials/NCT07070518
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Is NCT07070518 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies GV20-0251 for solid tumor cancer.
Treatment: GV20-0251 — This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Endometrial Cancer
Colorectal Cancer
Non-Small Cell Lung Carcinoma
Melanoma
Hepatocellular Carcinoma
Small Cell Lung Cancer
Disease stage
Metastatic disease required
measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST version 1.1)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care therapy
Refractory or intolerant to standard therapies, must have received the standard of care therapy
Cannot have received: anticancer therapy
Exception: within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of GV20-0251 on Cycle 1 Day 1 (C1D1), with the exceptions
Prior anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of GV20-0251 on Cycle 1 Day 1 (C1D1), with the exceptions
Cannot have received: radiation therapy
Exception: for symptomatic lesions within 14 days prior to C1D1 dosing
Radiation therapy for symptomatic lesions within 14 days prior to C1D1 dosing
Lab requirements
Cardiac function
No heart disease (NYHA ≥ Level II), myocardial infarction within the past 6 months, or unstable arrhythmia; QTcF > 470 msec, congenital long QT syndrome, or history of clinically significant ECG abnormalities (including pericarditis)
Participant with heart disease (NYHA ≥ Level II), myocardial infarction within the past 6 months, or unstable arrhythmia; Fridericia-corrected QT interval (QTcF) > 470 msec, or the presence of congenital long QT syndrome, or a history of clinically significant electrocardiogram (ECG) abnormalities (including pericarditis) that, in the investigator's judgment, may affect the subject's safety.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify